Therefore, to prove the prognostic effect of previously reported ARCH/CHIP for rapid fibrotic progression in pre-PMF [25] and for leukemic transformation in MDS [26] in the MF cohort, we analyzed an association between these mutations and outcomes (OS and PFS) in patients with prefibrotic, overt PMF, and SMF. This evidence concerns the gene TSLIG1 and myelodysplastic syndrome.